Skip to main content
Premium Trial:

Request an Annual Quote

Investment Firm to Buy 49 Percent Stake in Olink

NEW YORK (GenomeWeb News) – Nxt2b has signed an agreement to purchase 49 percent of all outstanding shares of Swedish protein and molecular technologies firm Olink Bioscience for an undisclosed amount.

The deal is expected to "accelerate the growth and value creation of the company by injecting knowledge, experience, and financial strength to complement Olink's unique product and technology position," Olink said in a statement.

"Together with Nxt2b, we have now created a foundation to take Olink to new levels of commercial success by combining our unique portfolio of technologies and products with the experience and financial strength of Nxt2b," Olink President and CEO Björn Ekström said.

Nxt2b is a privately owned investment company owned by Bengt Ågerup that focuses on equity investments in medical devices, specialty pharmaceutical companies, and technology and consumer firms.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.